Abstracts tagged "interleukins (IL)"

Abstract Number: 2684 • 2012 ACR/ARHP Annual Meeting
Cerebrospinal Fluid IL-6 and Anti-NMDA Receptor NR2 Antibodies As Surrogate Markers for CNS Disease Severity in SLE
Shunsei Hirohata, Yoshiyuki Arinuma and Eisuke Ogawa, Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Neuropsychiatric manifestations occur in approximately one-half of patients with SLE and may cause substantial impairment of quality of life as well as disability. Among…
Abstract Number: 2079 • 2012 ACR/ARHP Annual Meeting
Anti-Interleukin-6 Receptor Antibody Improves Systemic Osteoporosis in a Mice Model of Glucose-6-Phosphate Isomerase-Induced Arthritis
Hiroto Yoshida¹, Miho Suzuki¹, Misato Hashizume¹, Keisuke Tanaka², Masashi Shiina², Isao Matsumoto³, Takayuki Sumida³ and Yoshihiro Matsumoto², ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan, ³Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba City, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) have a high risk of osteoporosis and osteoporotic fracture. In addition to the primary risk factors for osteoporosis, osteoporosis…
Abstract Number: 899 • 2012 ACR/ARHP Annual Meeting
A Role for Soluble Interleukin-6 Receptor As an Antagonist of Interleukin-27 Signaling
Misato Hashizume¹, Keiko Esaki² and Yoshihiro Matsumoto¹, ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Discovery Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan
Background/Purpose: Recently, it has been reported that interleukin (IL)-27 treatment reduces inflammation and ameliorates arthritis in collagen-induced arthritis mice. IL-27 is a heterodimeric cytokine composed…
Abstract Number: 2021 • 2012 ACR/ARHP Annual Meeting
The Schedule of Administration of Canakinumab in Cryopyrin Associated Periodic Syndrome Is Driven by the Phenotype Severity Rather Than the Age
Roberta Caorsi¹, Loredana Lepore², Francesco Zulian³, Maria Alessio⁴, Achille Stabile⁵, Antonella Insalaco⁶, Martina Finetti¹, Antonella Battagliese⁴, Giorgia Martini⁷, Chiara Bibalo⁸, Alberto Martini⁹ and Marco Gattorno¹, ¹Second Division of Paediatrics, G. Gaslini Institute, Genova, Italy, ²Istituto Burlo Garofolo, Trieste, Italy, ³Department of Pediatrics, University of Padua, Padova, Italy, ⁴Department of Pediatrics,, Federico II Hospital, Napoli, Italy, ⁵DipartimentoPediatria, Policlinico Gemelli, Roma, Italy, ⁶Department of Pediatric Rheumatology, Ospedale Pediatrico Bambino Gesù, Roma, Italy, ⁷Department of Pediatrics,, University of Padua, Padua, Italy, ⁸Pediatrics-Univ of Trieste, Ospedale-Infantile Trieste, Trieste, Italy, ⁹Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH
Background/Purpose: to identify the optimal regimen for the treatment with Canakinumab in CAPS patients and, in patients receiving both Anakinra and Canakinumab during their disease…
Abstract Number: 901 • 2012 ACR/ARHP Annual Meeting
Colony-Stimulating Factor (CSF) Receptor 1 Blockade Overcomes Overlapping Effects of M-CSF and Interleukin-34 On Myeloid Differentiation and Gene Expression to Reduce Inflammation in Human and Murine Models of Rheumatoid Arthritis
Samuel Garcia¹, Linda M. Hartkamp², Inge E. van Es², Haishan Lin³, Li Long³, Emma L. Masteller³, Brian R. Wong³, Paul P. Tak⁴ and Kris A. Reedquist², ¹Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ³Five Prime Therapeutics, Inc., South San Francisco, CA, ⁴Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands
Background/Purpose: Disease activity and response to therapy in RA correlates with changes in synovial macrophage numbers and their products. M-CSF or IL-34 stimulation of their…
Abstract Number: 2031 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Anakinra in Patients with Deficiency of Interleukin-1 Receptor Antagonist
Gina A. Montealegre¹, Adriana Almeida de Jesus², Dawn C. Chapelle³, Paul Dancey⁴, Joost Frenkel⁵, Annet van Royen-Kerkhoff⁶, Ronit Herzog⁷, Giovanna Ciocca⁸, Rafael F. Rivas-Chacon⁸, Ann M. Reed⁹, Nicole Plass³, Ivona Aksentijevich¹⁰, Polly J. Ferguson¹¹, Suvimol C. Hill¹², Edward Cowen¹³ and Raphaela T. Goldbach-Mansky³, ¹NIAMS, Bethesda, MD, ²Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ³Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ⁴Health Science Centre, Memorial University of Newfoundland, St Johns, Canada, ⁵Wilhelmina Childrens Hospital, University of Utrecht, Utrecht, Netherlands, ⁶University of Utrecht, Utrecht, Netherlands, ⁷Cornell University, New York, NY, ⁸Miami Children's Hospital, Miami, FL, ⁹Rheumatology, Mayo Clinic, Rochester, MN, ¹⁰Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ¹¹Dept of Pediatrics--Rheum, University of Iowa Carver College of Medicine, Iowa City, IA, ¹²Radiology and Imaging Sciences, NIH Clinical Center, Bethesda, MD, ¹³Dermatology Consultation Servce, National Cancer Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Deficiency of interleukin-1 receptor antagonist (DIRA) is a neonatal-onset autoinflammatory syndrome caused by mutations in IL1RN gene and clinically characterized by a perinatal onset…
Abstract Number: 877 • 2012 ACR/ARHP Annual Meeting
Aberrant Expression of BAFF Receptor (BR3) in Peripheral Monocytes of Patients with Primary Sjögren’s Syndrome Impacts Abnormal Activation of BAFF Signaling Through IKK-Alphaand IKK-Beta
Keiko Yoshimoto¹, Maiko Tanaka², Masako Kojima², Hideko Ogata², Hideto Kameda¹, Katsuya Suzuki¹, Tohru Abe³ and Tsutomu Takeuchi⁴, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Dept Int Med Saitama Med Ctr, Saitama Medical School, Kawagoe-shi Saitama, Japan, ⁴Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: B cell activating factor belonging to the TNF superfamily (BAFF) regulates proliferation, differentiation and survival of B cells and plays a pivotal role in…
Abstract Number: 1805 • 2012 ACR/ARHP Annual Meeting
The Pro-Fibrotic Cytokines IL-33 and IL-13 Modulates Dermal Fibrosis Via the A2A Adenosine Receptor
Ross C. Radusky¹, Jessica L. Feig², Bruce N. Cronstein³, Andrew G. Franks Jr.⁴ and Edwin SL Chan¹, ¹Medicine, New York University School of Medicine, New York, NY, ²Medicine. Department of Translational Medicine, New York University School of Medicine, New York, NY, ³Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY, ⁴Dermatology & Medicine (Rheumatology), New York University, New York, NY
Background/Purpose: We have previously demonstrated that the nucleoside adenosine mediates collagen production and induce dermal fibrosis in in vitro and in vivo models. IL–13 expression…
Abstract Number: 888 • 2012 ACR/ARHP Annual Meeting
Plasma Cells Express the Novel Cytokine Interleukin-36α in Psoriatic and Rheumatoid Arthritis Synovium
Anja Derer¹, Silke Frey², Maria-Elena Messbacher², Serena Bugatti³, Dominique L. Baeten⁴, Carlomaurizio Montecucco⁵, Georg A. Schett¹ and Axel J. Hueber⁶, ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Internal Medicine 3, University of Erlangen, Erlangen, Germany, ³Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy, ⁴Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵Division of Rheumatology, University of Pavia School of Medicine, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, ⁶Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: IL-36α is a recent described IL-1 cytokine family member with proinflammatory and clear pathogenic properties in psoriasis. Aim of this study was to determine…
Abstract Number: 1674 • 2012 ACR/ARHP Annual Meeting
Myeloid Related Proteins Induce Muscle Derived Inflammatory Mediators in Juvenile Dermatomyositis
Kiran Nistala¹, Hemlata Varsani², Helmut Wittkowski³, Thomas Vogl⁴, Petra Krol⁵, Vanita Shah², Kamel Mamchaoui⁶, Paul Brogan², Johannes Roth⁷ and Lucy R. Wedderburn², ¹Paediatric Rheumatology International Trials Organization (PRINTO), Genova, Italy, ²Rheumatology Unit , Institute of Child Health, University College London (UCL), London, United Kingdom, ³Muenster, Germany, ⁴Institute of Immunology, University of Muenster, Muenster, Germany, ⁵Rheumatology Unit, Department of Paediatrics and Adolescent Medicine, Prague, Czech Republic, ⁶Institut de Myologie, Paris, France, ⁷Immunology, Institute of Immunology University of Muenster, Muenster, Germany
Background/Purpose: The etiopathogenesis of Juvenile Dermatomyositis (JDM) remains poorly understood. In particular the contribution of monocytes or macrophages, which are frequently observed to be an…
Abstract Number: 813 • 2012 ACR/ARHP Annual Meeting
Rilonacept for Gout Flare Prophylaxis in Patients with Chronic Kidney Disease: Analysis of 3 Clinical Trials
Robert Terkeltaub¹, Robert R. Evans², Steven P. Weinstein³, Richard Wu⁴ and H. Ralph Schumacher⁵, ¹Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ²Clinical Sciences, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ³Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁴BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Department of Medicine, University of Pennsylvania and VA Medical Center, Philadelphia, PA
Background/Purpose: Gout flare (GF) prophylaxis in patients (pts) with chronic kidney disease (CKD; estimated glomerular filtration rate [eGFR]

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].